1246-P: Magnitude of Intentional Weight Reduction and Associated Clinical Outcomes

Abstract

Purpose: To describe the association of BMI reduction with clinical outcomes (medication utilization, HbA1c, and blood pressure) in adults undergoing medical intervention for weight reduction. Methods: Optum’s Market Clarity database (Study Period: 2007-2020) was used to identify adults with overweight/obesity with a medical intervention for weight reduction (surgery, procedure, anti-obesity medication, or lifestyle) whose weight after a 3-year period was less than or equal to their pre-intervention weight (date of weight: index). Patients were grouped by percent BMI change (Figure 1). Outcomes included change in 6-month pre-index versus 6-month follow-up (starting after the 3-year period) for HbA1c and blood pressure in patients with measures in both periods, and change in condition-specific pharmacy utilization for patients with the condition during pre-index. Results: There were n=127,267 patients meeting study criteria. Mean Rx utilization during follow-up decreased (relative to pre-index) as BMI reduction increased, (p<0.001; Figure 1a-1c) with groups achieving ≥15% BMI reduction having lower mean utilization in follow-up versus pre-index. Greater BMI reduction was also associated with improvements in HbA1c and blood pressure (p<0.001; Figure 1d-1f). Conclusions: Higher BMI reduction groups had greater mean improvements in clinical measures while mean medication utilization decreased. Disclosure H.Kan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. J.P.Dunn: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. L.Bengtson: Other Relationship; Eli Lilly and Company. N.Ahmad: Employee; Eli Lilly and Company. J.P.Bae: None. N.Gronroos: Other Relationship; Eli Lilly and Company. C.Landis: Other Relationship; Eli Lilly and Company. C.Chinthammit: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. A.H.Owora: None. N.A.Gletsu miller: Research Support; Lilly.